News & Updates

SkylineDx Announces Presentation of New Data Highlighting the Predictive Power of the CP-GEP Merlin Test for T1a Cutaneous Melanoma Patients at the 21st International Congress of the Society for Melanoma Research

10/17/2024

The Merlin Test (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, Oct. 11, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory,…

Read More

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

10/16/2024

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD) /Multiple Ascending Dose (MAD) and food effects (FE) and includes multiple dose treatment of UC patients; Global UC market is expected…

Read More

Vaxess Receives National Institutes of Health Grant to Explore Administering Type 2 Diabetes Treatment via the MIMIX™ Transdermal Patch Platform

10/14/2024

The National Institute of Diabetes and Digestive and Kidney Diseases Awards Vaxess SBIR Phase I Funding to Test Company’s MIMIX Transdermal Patch Platform in Administering GLP-1 RA Therapies Excerpt from the Press Release: CAMBRIDGE, Mass., October 1, 2024 — Vaxess Technologies, Inc., a biotech company developing a novel transdermal patch technology to transform home delivery…

Read More

New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

10/11/2024

Findings are from the prospective, multicenter VANDAAM trial Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease.…

Read More

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

10/10/2024

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc.…

Read More

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

10/09/2024

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare…

Read More

Integrated Biosciences Raises $17 Million to Accelerate Development of Drugs Targeting Age-Related Diseases

10/08/2024

Sutter Hill Ventures-led round will accelerate drug pipeline development and advance commercialization efforts, bringing science a step closer to targeting aging Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has…

Read More

Mission Bio Launches Innovative Single-cell Genome Integrity Solution to Measure Whole Genome Copy Number Variation in Advanced Therapies and Tumor Samples

10/07/2024

First-of-its-kind DNA assay unlocks high-throughput CNV insights critical to cell and gene therapy (CGT) safety and characterizing tumor heterogeneity Excerpt from the Press Release: SAN FRANCISCO, Calif., Sep. 26, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. The new…

Read More

Schedule your personalized live demo with Christopher Kata and the TrialStat team during Clinical Outsourcing Group Bay Area Meeting October 8th – 9th!

10/04/2024

Christopher Kata and the TrialStat team are exhibiting at this years Clinical Outsourcing Group Bay Area meeting on October 8th – 9th in booth #13. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #13 at your convenience! We’re looking forward to…

Read More

Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

10/04/2024

Late Breaking Surgical Safety Data to be Presented This Week at MDS International Congress of Parkinson’s Disease and Movement Disorders Excerpt from the Press Release: SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives